Personalized tamoxifen: a step closer but miles to go.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 20651057.
- Also identified by DOI 10.1158/1078-0432.CCR-10-1506 and PMC identifier 2980759.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Genetic variants in CYP2D6 lead to reduced conversion of tamoxifen to the active metabolite endoxifen. However, the role of the CYP2D6 genotype in predicting tamoxifen-associated outcomes remains controversial. Accurate assignment of the CYP2D6 genotype in archival tissues is crucial for future studies attempting to determine risk prediction of outcomes in tamoxifen-treated individuals.
Medical subject headings
- Breast Neoplasms
- Cytochrome P-450 CYP2D6
- Polymorphism, Genetic
- Tamoxifen